Navigation Links
Listing Review initiated by the Toronto Stock Exchange
Date:11/3/2008

TORONTO, Nov. 3 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) today announced it has been notified by the Toronto Stock Exchange ("TSX") that it is reviewing the eligibility of the Company's common shares for continued listing on the TSX.

The Company is being reviewed under the TSX's Remedial Review Process and has been granted 210 days to comply with all requirements for continued listing. If the Company cannot demonstrate that it meets all TSX listing requirements on or before June 2, 2009, the Company's common shares will be delisted 30 days from such date. A meeting of the TSX's Listings Committee is scheduled to be held on May 28, 2009 to consider whether to delist the common shares of the Company. The TSX has also advised that, if the TSX becomes aware of additional negative developments such that the continued trading or listing of the Company's shares is contrary to the public interest, an expedited listing review could be initiated.

Over the next months, while the Company awaits their FDA appeal decision and other corporate developments, PreMD will evaluate its options in dealing with the TSX and will provide updates as they become available.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include PREVU* POC and PREVU* LT, both non-invasive skin cholesterol tests. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Standard Management Announces OTCBB Listing
2. Pharsight Files Application for Nasdaq Capital Market Listing
3. InfoLogix Announces Approval for NASDAQ Listing
4. AKELA Pharma Inc. announces U.S. public offering and proposed listing
5. XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
6. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
7. Cash Technologies Discusses AMEX Listing Requirements
8. MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
9. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
10. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
11. Elbit Imaging Ltd. Selected for Listing on Nasdaq Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... July 28, 2017 , ... ... of its budget on nutrition assistance programs. , Right now the most public ... . However, changes to other programs are under consideration, including WIC (Women, Infants, ...
(Date:7/28/2017)... ... July 28, 2017 , ... Kevin Harrington, one of the original Sharks from hit reality ... of a new DRTV campaign with My Real Earth. , Most people put their healthcare ... just as important as what we put in our bodies. After all, the skin is ...
(Date:7/28/2017)... OR (PRWEB) , ... July 28, 2017 , ... Date ... http://www.GlobalDragonTV.com , Like millions of first generation immigrants before her, Rose Hong ... beneficiary of generosity and sacrifice on the part of loving parents who made sure ...
(Date:7/28/2017)... ... 2017 , ... The DuPage County law firm of Mirabella Kincaid Frederick ... Ms. Cusack joins the team ready to provide clients with vigorous representation in ... in Peoria, Illinois, with a BA in Social Work. She earned her JD from ...
(Date:7/28/2017)... ... July 28, 2017 , ... As many parents, students, and teachers are getting ... sharpen mental acuity and address mental fatigue that can accompany long study hours, homework ... that can not only helps with school work but also in day-to-day functions on ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat company, ... a program for CleverCap LITE, a technology designed to ... to deliver innovative health technology solutions and services that ... CleverCap LITE offers medication monitoring ... bottle cover: Records ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
Breaking Medicine Technology: